

SMS Lifesciences India Limited

Registered & Corporate Office:

Plot No. 19-III, Road No. 71, Opp. Bharatiya Vidya Bhavan Public School,

Jubilee Hills, Hyderabad - 500 096, Telangana, INDIA. Tel: +91-040-6628 8888, Fax: +91-40-2355 1401

CIN: U74930TG2006PLC050223 Email: info@smslife.in, www.smslife.in

Date: 13th November, 2018

To,
The Manager,
Corporate Filings Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001

The Manager, Listing Compliance Department, National Stock Exchange of India Ltd. Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051.

Security Code: 540679

Symbol: SMSLIFE

Dear Sir/Madam,

Subject: Outcome of the Board Meeting held on 13th November, 2018.

With reference to the above cited subject, we would like to inform you that the Board of Directors of the Company at their meeting held on today, inter-alia considered and approved the Unaudited financial results for the Quarter and halkf year ended on 30th September, 2018 along with the Limited Review Report as enclosed herewith.

The Meeting commenced at 14.00 hrs and concluded at 15.10 hrs.

Please take the above information on your records.

Hyderabad

Thanking You,

Yours Faithfully,

For SMS Lifesciences India Limited

Pavan Pise

Company Secretary

SMS LIFESCIENCES INDIA Limited

Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee Hills, Hyderabad - 500 096 Statement of Standalone Un-Audited Financial Results for the Quarter and Half Year Ended 30th September, 2018

(Rs. In Lakhs)

		Quarter Ended			Half Year ended		Year ended	
S.No	Particulars	30.09.2018	30.06.2018	30.09.2017	30.09.2018	30.09.2017	31.03.2018	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
1	Revenue From Operations	8,920.24	5,987.87	5,104.37	14,908.11	9,687.56	21,748.17	
2	Other Income	76.57	51.28	76.62	127.85	178.70	307.72	
-	Carlot income							
3	Total Revenue	8,996.81	6,039.15	5,180.99	15,035.96	9,866.26	22,055.89	
4	Expenses							
	(a) Cost of Materials Consumed	6,202.69	5,189.20	3,894.63	11,391.89	6,705.76	13,501.25	
	(b) Changes in Inventories	(132.48)	(1,776.91)	(657.32)	(1,909.39)	(1,346.06)	(206.21	
	(c) Central Excise Duty	- 1	-	-	-	449.39	449.39	
	(d) Manufacturing Expenses	1,268.49	1,114.54	956.20	2,383.03	1,975.79	3,950.60	
	(e) Employee Benefits Expense	501.37	514.20	415.11	1,015.57	860.10	1,764.61	
	(f) Finance Cost	133.34	117.36	88.96	250.70	224.41	417.92	
	(g) Depreciation and Amortization Expense	139.78	138.01	143.73	277.79	284.70	570.36	
	(h) Other Expenses	273.83	302.59	230.33	576.42	443.86	968.31	
	Total Expenses - (a to f)	8,387.02	5,598.99	5,071.64	13,986.01	9,597.95	21,416.23	
	, , , , , , , , , , , , , , , , , , ,	-,			,	,		
5	Profit before Exceptional and Extraordinary Items and Tax (3-4)	609.79	440.16	109.35	1,049.95	268.31	639.66	
6	Exceptional items	- 2	-	-	-	-	-	
7	Profit before Extraordinary Items and Tax (5-6)	609.79	440.16	109.35	1,049.95	268.31	639.66	
8	Extraordinary Items	-	-	-	-	-	-	
9	Profit before Tax (7-8)	609.79	440.16	109.35	1,049.95	268.31	639.66	
10	Tax Expenses							
	(1) Current Tax							
	(a) relating to Current Year	185.00	125.00	35.00	310.00	90.00	170.00	
	(b) relating to Earlier year						(133.72	
	(2) Deferred Tax	(16.28)	8.00	(27.24)	(8.28)	(27.09)	(46.75	
11	Net Profit / (Loss) for the Period (9-10)	441.07	307.16	101.59	748.23	205.40	650.13	
12	Other Comprehensive Income (OCI):							
12	Items that will not be reclassified to profit or Loss:	(2.83)	(2.36)	(9.52)	(5.19)	(16.04)	9.44	
	Tax on Items that will not be reclassified to profit or Loss:	(0.79)	(0.82)	(3.52)	(1.61)		2.63	
	Tax on items that will not be reclassified to profit of Loss.	(2.04)	(1.54)	(9.52)	(3.59)			
13	Total comprehensive Income for the period (11+12)	439.03	305.62	92.07	744.65	194.91	656.94	
	,							
14	Earning Per Equity Share							
	(of Rs.10/ each) (not annualised)							
	Basic / Diluted.	14.59	10.16	3.36	24.75	6.79	21.50	
	Paid-up equity share capital (Face Value of Rs 10/ each)	302.33	302.33	302.33	302.33	302.33	302.33	
	Reserves excluding Revaluation Reserves as per balance sheet of							
	previous accounting year						8,538.48	
	provided doodanting your							



Statement of Assets & Liabilities as at 30th September, 2018

(Rs.in Lakhs)

Otate	ment of Assets & Clabilities as at 30th September, 2010		(RS.III Lakins)
		As at	As at
Sr.No.	Particulars	30.09.2018	31.03.2018
		(Unaudited)	(Audited)
Α	ASSETS	(Citation)	(Fileday)
10000	Non-Current Assets		
- 1	(a) Property, Plant and Equipment	7,470.85	6,835.84
	(b) Capital Work-in-Progress	446.58	708.80
	(c) Intangible Assets	2.08	2.38
- 1	(d) investment Property	80.03	80.20
	(e) Financial Assets:	80.03	00.20
	(i) Investments	0.504.40	500.05
		2,581.40	500.35
	(ii) Bank Balances	114.72	107.88
	(iii) Other Financial Assets	195.82	196.69
	(e) Other Non-Current Assets	261.88	361.56
	Sub Total :Non-Current Assets	11,153.36	8,793.70
-	Current Assets		
	(a) Inventories	8,039.39	4,931.61
	(b) Financial Assets		
	(i) Trade Receivables	2,779.22	2,707.56
	(ii) Cash and Cash Equivalents	34.05	43.58
	(iii) Bank Balances		
	(Other than (ii) above)	32.00	32.52
	(iv) Other Financial Assets	2.37	14.25
1	(c) Other Current Assets	1,338.47	1,142.26
	(d) Current Tax Asset (Net)	1,000.47	1,142.20
	(a) Carrent Tax 7.65ct (NCt)		-
ł	Sub Total : Current Assets	12,225.50	8,871.78
- 1	TOTAL ASSETS	23,378.86	17,665.48
В	EQUITY AND LIABILITIES		
1	Equity:		
	(a) Equity Share Capital	302.33	302.33
	(b) Other Equity	9,283.13	8,538.48
ŀ	Sub-Total -Shareholders' funds	9,585.46	8,840.81
ŀ	Liabilities:	0,000110	0,010.01
	Non-Current Liabilities		
	(a) Financial Liabilities		
		4 242 26	4 540 07
	(i) Borrowings	1,212.36	1,519.07
	(b) Provisions	220.79	199.75
	(c) Deferred Tax Liabilities (net)	706.85	716.74
	Sub-Total -Non-Current Liabilities	2,140.00	2,435.56
	Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	1,349.01	599.31
	(ii) Trade Payables:	8,786.51	4,439.25
	(iii) Other Financial Liabilities	651.61	1,117.99
	(b) Provisions	63.77	59.81
	(c) Other Current Liabilities	739.44	138.23
	(d) Current Tax Liabilities (Net)	63.06	34.52
Ces	Ing		
ences	Sub-Total - Current Liabilities	11,653.40	6,389.11
(TOTAL - EQUITY AND LIABILITIES	23,378.86	17,665.48

Notes:

- The above standalone Financial Results have been reviewed and recomended by the Audit Committee on 13th November, 2018 and have been approved by the Board of Directors at its meeting held on 13th November, 2018.
- 2 Results for the quarter ended 30th September, 2018 were subjected to 'Limited Review' by the Auditors.
- The above results are in accordance with the companies (Indian Accounting Standards) rules, 2015, (Ind AS) as ammended by Company (Ind AS) (ammendement) Rules, 2016, notified under Section 133 of the Companies Act 2013, read with relavent Rules issued there under and other accounting principals generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- Mahi Drugs has become 100% Wholly Owned Subsidary of the company with effect from 17th September 2018 and as per Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the company has opted to publish quarterly unaudited standalone results and to publish consolidated results at the year end.
- The Company is engaged in the manufacturing Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- Post implementation of Goods and Service Tax (GST) effective from I st July, 2017, revenue is reported net of GST as per Ind AS-18. Revenue, however, is reported inclusive of excise duty for a part of the period ended 30th September, 2017. Had the previously reported revenue been shown net of excise duty, comparative revenue of the company would have been as under:

	Por	ticulars	Quarter ended			Half Year ended		Year ended
	Fal		30.09.2018	30.06.2018	30.09.2017	30.09.2018	30.09.2017	31.03.2018
R	Revenue from operations (net of e	excise duty)	8,920.24	5,987.87	5,104.37	14,908.11	9,242.59	21,303.20

Place: Hyderabad Date: 13-11-2018 Hyderabad In the state of the s

For SMS LifeSciences India Limited

T V V S N Murthy Managing Director

RAMBABU & CO., CHARTERED ACCOUNTANTS

Phone : 23311587

23318152

Fax: 23397182

Limited Review Report

To
The Board of Directors
SMS LIFESCIENCES INDIA LIMITED
Hyderabad.

We have reviewed the accompanying statement of unaudited financial results of SMS LIFESCIENCES INDIA LIMITED ("the Company"), for the quarter ended 30th September 2018 ("the statement"), being submitted by the company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No.CIR/CFD/FAC/62/2016 dated 5th July,2016.

This statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the aforesaid Indian Accounting standards and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No.CIR/CFD/FAC/62/2016 dated 5th July,2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad Date: 13-11-2018 For Rambabu & Co., Chartered Accountants

Reg. Nø.0029765

GVL Prasad

Partner

M. No. 026548